- Presented preclinical data demonstrating abscopal immune effect in pancreatic murine tumor models at ESTRO 2024
- First patient with liver metastases treated in a feasibility and safety study of
- Patient recruitment for ReSTART
- Cash, cash equivalents, deposits & restricted deposits balance of $80.7 million with runway of at least two years -
"This year we remain focused on advancing our ReSTART
Recent Corporate Highlights:
- In May, preclinical data demonstrating an abscopal immune effect in pancreatic murine tumor models was presented at ESTRO 2024
Congress inGlasgow . Initial data demonstrates significant reduction in distant pancreatic cancer tumor growth rate starting from three weeks after first tumor is treated withAlpha DaRT alone. The effect was seen across both Panc02 and KPC tumor models. - In May, the first patient with liver cancer metastases was treated in a feasibility and safety study of
Alpha DaRT atMcGill University Health Center inMontreal, Canada . The trial aims to recruit up to 10 patients who are eligible for a two-staged hepatectomy to resect liver metastases of colorectal cancer. For more information, please refer to https://clinicaltrials.gov/study/NCT05829291. - In May, the first patient was treated in a clinical trial at the Rambam Health Care Campus in
Haifa, Israel examining the use ofAlpha DaRT for focal treatment of recurrent prostate cancer tumors. The trial aims to recruit up to 10 patients with recurrent, non-metastatic prostate adenocarcinoma. For more information, please refer to https://www.clinicaltrials.gov/study/NCT06202248.
Upcoming 2024 Milestones
- Planning treatment of the first patient in the Israeli recurrent lung cancer safety and feasibility trial in Q2 2024. The trial is currently open for recruitment; for more information please see here: https://www.clinicaltrials.gov/study/NCT05632913
- Targeting first brain cancer treatment in H2 2024.
- Targeting completion of patient recruitment in the ReSTART
U.S. multi-center pivotal trial in recurrent cutaneous squamous cell carcinoma in H2 2024. The trial is currently open for recruitment; for more information please see here: https://www.clinicaltrials.gov/study/NCT05323253 - Targeting completion of patient recruitment in the Canadian advanced inoperable pancreatic cancer study in
Montreal in H2 2024. The trial is currently open for recruitment; for more information please see here: https://www.clinicaltrials.gov/study/NCT04002479 - Anticipating response from PMDA in
Japan by year-end 2024 for pre-market approval forAlpha DaRT in patients with recurrent head and neck cancer.
Financial results for quarter ended
R&D expenses for the quarter ended
Marketing expenses for the quarter ended
G&A expenses for the quarter ended
Financial income, net, for the quarter ended
For the quarter ended
Balance Sheet Highlights
As of
About Alpha DaRT™
About
Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof.
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. When used herein, words including "anticipate," "being," "will," "plan," "may," "continue," and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Alpha Tau's current expectations and various assumptions. Alpha Tau believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Alpha Tau may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: (i) Alpha Tau's ability to receive regulatory approval for its
Investor Relations Contact:
IR@alphatau.com
CONSOLIDATED BALANCE SHEET | |||||||
2023 | 2024 | ||||||
Audited | Unaudited | ||||||
ASSETS | |||||||
CURRENT ASSETS: | |||||||
Cash and cash equivalents | $ | 12,657 | $ | 7,296 | |||
Short-term deposits | 69,131 | 70,257 | |||||
Restricted deposits | 3,152 | 3,124 | |||||
Prepaid expenses and other receivables | 816 | 527 | |||||
Total current assets | 85,756 | 81,204 | |||||
LONG-TERM ASSETS: | |||||||
Long term prepaid expenses | 471 | 465 | |||||
Property and equipment, net | 12,798 | 12,592 | |||||
Right-of-use asset | 8,363 | 8,183 | |||||
Total long-term assets | 21,632 | 21,240 | |||||
Total assets | $ | 107,388 | $ | 102,444 | |||
CONSOLIDATED BALANCE SHEET | ||||||||
2023 | 2024 | |||||||
Audited | Unaudited | |||||||
LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||
CURRENT LIABILITIES: | ||||||||
Trade Payables | $ | 2,566 | $ | 2,459 | ||||
Other payables and accrued expenses | 3,474 | 3,491 | ||||||
Current maturities of operating lease liabilities | 1,062 | 1,050 | ||||||
Total current liabilities | 7,102 | 7,000 | ||||||
LONG-TERM LIABILITIES: | ||||||||
Long-term loan | 5,610 | 5,526 | ||||||
Warrants liability | 3,597 | 4,486 | ||||||
Operating lease liabilities | 6,604 | 6,366 | ||||||
Total long-term liabilities | 15,811 | 16,378 | ||||||
Total liabilities | 22,913 | 23,378 | ||||||
SHAREHOLDERS' EQUITY: | ||||||||
Share capital | ||||||||
Ordinary shares of no-par value per share – Authorized: 362,116,800 shares as of | - | - | ||||||
Additional paid-in capital | 200,234 | 202,806 | ||||||
Accumulated deficit | (115,759 | ) | (123,740 | ) | ||||
Total shareholders' equity | 84,475 | 79,066 | ||||||
Total liabilities and shareholders' equity | $ | 107,388 | $ | 102,444 | ||||
CONSOLIDATED STATEMENT OF OPERATIONS | |||||||
Three months ended | |||||||
2023 | 2024 | ||||||
Unaudited | |||||||
Research and development, net | $ | 6,306 | $ | 6,448 | |||
Marketing expenses | 400 | 533 | |||||
General and administrative expenses | 1,938 | 1,443 | |||||
Total operating loss | 8,644 | 8,424 | |||||
Financial income, net | (478 | ) | (444 | ) | |||
Loss before taxes on income | 8,166 | 7,980 | |||||
Tax on income | 21 | 1 | |||||
Net loss | 8,187 | 7,981 | |||||
Net comprehensive loss | 8,187 | 7,981 | |||||
Net loss per share, basic and diluted | $ | (0.12 | ) | $ | (0.11 | ) | |
Weighted-average shares used in computing net loss per share, basic and diluted | 69,205,654 | 69,714,250 | |||||
Source:
2024 GlobeNewswire, Inc., source